4//SEC Filing
Gangloff Scott A. 4
Accession 0000950170-25-110352
CIK 0001744659other
Filed
Aug 18, 8:00 PM ET
Accepted
Aug 19, 9:32 PM ET
Size
6.8 KB
Accession
0000950170-25-110352
Insider Transaction Report
Form 4
Gangloff Scott A.
Chief Technology Officer
Transactions
- Exercise/Conversion
Common Stock
2025-08-15$19.62/sh+2,600$51,012→ 26,351 total - Exercise/Conversion
Stock option (Right to Buy)
2025-08-15−2,600→ 17,784 totalExercise: $19.62Exp: 2034-04-28→ Common Stock (20,384 underlying)
Footnotes (1)
- [F1]Twenty-five (25) percent of the shares subject to this option shall vest and become exercisable on April 29, 2025, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Documents
Issuer
Akero Therapeutics, Inc.
CIK 0001744659
Entity typeother
Related Parties
1- filerCIK 0001663253
Filing Metadata
- Form type
- 4
- Filed
- Aug 18, 8:00 PM ET
- Accepted
- Aug 19, 9:32 PM ET
- Size
- 6.8 KB